Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).
Joshua F. Zeidner
No relevant relationships to disclose
Matthew C. Foster
No relevant relationships to disclose
Amanda Blackford
No relevant relationships to disclose
Mark Robert Litzow
No relevant relationships to disclose
Lawrence Morris
No relevant relationships to disclose
Stephen Anthony Strickland
No relevant relationships to disclose
Jeffrey E. Lancet
No relevant relationships to disclose
Prithviraj Bose
No relevant relationships to disclose
M. Yair Levy
No relevant relationships to disclose
Raoul Tibes
No relevant relationships to disclose
Ivana Gojo
No relevant relationships to disclose
Christopher D Gocke
No relevant relationships to disclose
Gary L. Rosner
No relevant relationships to disclose
Jacqueline Greer
No relevant relationships to disclose
Joan M Cain
No relevant relationships to disclose
Richard F. Little
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
B Douglas Smith
No relevant relationships to disclose
Judith E. Karp
No relevant relationships to disclose